30. Heidenreich A., Höltl W., Albrecht W. et al. Testis-preserving surgery in bilateral testicular germ cell tumours. Br J Urol 1997;79:253–7.
31. Трякин А.А. Лекарственное и комбинированное лечение несеминомных герминогенных опухолей у мужчин. Дис. ... д-ра мед. наук. М., 2015. 254 с.
32. Cohn-Cedermark G., Stahl O., Tandstad T. Surveillance vs. adjuvant therapy of clinical stage I testicular tumors-a review and the SWENOTECA experience. . Andrology 2015;3:102–10.
33. Albers P. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I NSGCT:. AUO trial AH 01/94 by the German Testicular Cancer Study. J Clin Oncol 2008;26(18):2966–72.
34. Fedyanin M, Tryakin A, Bulanov A, et al. Chemotherapy intensification in patients with advanced seminoma and adverse prognostic factors. J Cancer Res Clin Oncol. 2015 Jul;141(7):1259-64.
35. Tran B., Ruiz-Morales J.M., Billalabeitia E.G. Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3). Cancer Med. 2019 Nov 12. doi: 10.1002/cam4.2674. [Epub ahead of print].
36. Tryakin A, Fedyanin M, Bulanov A, et al. Dose-reduced first cycle of chemotherapy for prevention of life-threatening acute complications in nonseminomatous germ cell tumor patients with ultra high tumor markers and/or poor performance status. J Cancer Res Clin Oncol. 2018 Sep;144(9):1817-1823.
37. Feldman D.R., Lorch A., Kramar A. et al. Brain metastases in patients with germ cell tumors: prognostic factors and treatment options-an analysis from the Global Germ Cell Cancer Group. J Clin Oncol 2016;34(4):345–51.
38. Daneshmand S., Albers P., Fossa S.D. et al. Contemporary management of postchemotherapy testis cancer. EurUrol 2012;62:867–76.
39. Tryakin A., Fedyanin M., Mitin A. et al. Complete disappearance of retroperitoneal lymph nodes after induction chemotherapy in advanced nonseminomatous germ cell tumors (NSGCT): is there a place for adjunctive surgery? J Clin Oncol 2012;30(15 suppl).
40. Kollmannsberger C. et. al. Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. . J Clin Oncol 2010;28:537.
41. De Santis M., Becherer A., Bokemeyer C. et al. 2-18Fluoro-deoxy-D-glucose positron emis-sion tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004;22:1034–9.
42. Cathomas R., Klingbiel D., Bernard B. et al. Questioning the value of fluorodeoxyglucose positron emission tomography for residual lesions after chemotherapy for metastatic seminoma: results of an International Global Germ Cell Cancer Group Registry. J Clin Oncol 2018;4:JCO1800210. .
43. Motzer R.J., Sheinfeld J., Mazumdar M. et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 2000;18(12):2413–8. .
44. Varuni Kondagunta, Jennifer Bacik, Alessia Donadio,et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol. 2005 Sep 20;23(27):6549-55..
45. Loehrer P.J., Gonin R., Nichols C.R. et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 1998;16:2500–4.
46. Donadio A.C., Motzer R.J., Bajorin D.F. et al. Chemotherapy for teratoma with malignant transformation. . J Clin Oncol 2003;21(23):4285–91.
47. S., Daneshmand. Role of surgical resection for refractory germ cell tumors. Urol Oncol 2015;33(8):370–8.
58. Silver J.K., Baima J. Cancer prehabilitation: an opportunity to decrease treatment-related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am J Phys Med Rehabil 2013;92(8):715–27.
59. Nilsson H., Angeras U., Bock D. et al. Is preoperative physical activity related to post-surgery recovery? A cohort study of patients with breast cancer. BMJ Open 2016;6(1):e007997.
60. Nicole L Stout, Daniel Santa Mina, Kathleen D Lyons, Karen Robb, Julie K Silver A systematic review of rehabilitation and exercise recommendations in oncology guidelines. CA Cancer J Clin. 2021 Mar;71(2):149-175. doi: 10.3322/caac.21639.
61. Tsimopoulou I., Pasquali S., Howard R. et al. Psychological Prehabilitation Before Cancer Surgery: A Systematic Review. Ann Surg Oncol 2015;22(13):4117–23.
62. Swarm R., Abernethy A.P., Anghelescu D.L. et al. Adult cancer pain. J Natl Compr Canc Netw 2010;8:1046–86.
63. Azhar R.A., Bochner B., Catto J. et al. Enhanced recovery after urological surgery: a contemporary systematic review of outcomes, key elements, and research needs. Eur Urol 2016;70(1):176–87.
64. Nilsson H., Angeras U., Bock D. et al. Is preoperative physical activity related to post-surgery recovery? A cohort study of patients with breast cancer. BMJ Open 2016;6(1):e007997.
65. Shin K.Y., Guo Y., Konzen B. et al. Inpatient cancer rehabilitation: the experience of a national comprehensive cancer center. Am J Phys Med Rehabil 2011;90(5):63–8.
66. Shehadeh A., El Dahleh M., Salem A. et al. Standardization of rehabilitation after limb salvage surgery for sarcomas improves patients" outcome. Hematol Oncol Stem Cell Ther 2013;6(3–4):105–11.
67. Fallon M., Giusti R., Aielli F. et al. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. . Ann Oncol 2018;29(Suppl 4):iv166–91.
68. Cox C.L., Montgomery M., Oeffinger K.C. et al. Promoting physical activity in childhood cancer survivors: results from the Childhood Cancer Survivor Study. Cancer 2009;115(3):642–54.